Metagenomi, Inc. Stock Plummets to New 52-Week Low of $1.22

Metagenomi, Inc., a microcap player in the Pharmaceuticals & Biotechnology sector, has reached a new 52-week low of USD 1.22 as of June 9, 2026. This significant decline marks a staggering 80.9% drop in the company's stock price over the past year, contrasting sharply with the S&P 500's performance, which has seen a gain of 22.99% during the same period. The company's financial metrics reflect ongoing difficulties, with a return on equity of -54.59% and a debt-to-equity ratio of -0.98. Additionally, Metagenomi has reported negative results for five consecutive quarters, indicating persistent challenges in its operational performance. The price-to-book ratio stands at 0.31, suggesting that the stock is trading below its book value. With a market capitalization of USD 50 million, Metagenomi's stock has underperformed not only in the long term but also in the near term, generating a return of -25.43% over the last year. The company's raw material costs have surged by 104.78% year-over-year, further complicating its financial landscape.